Clinical trial

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

NCT00862849

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Insulin Lispro Normalized identity: insulin lisproView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Regular Human Insulin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention rHuPH20 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-03-01

PhasePHASE1

Conditions

Diabetes Mellitusverified · MONDO: diabetes mellitus

Interventions

Insulin LisproDRUG · verified · RxNorm: insulin lispro

Regular Human InsulinDRUG

rHuPH20DRUG

Sponsors & collaborators

Halozyme Therapeuticslead sponsor

Mapped research locations

Chula VistaCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00862849 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.